by Clinical Neuropsychologist | Thursday, August 22, 2024 | Dementia
Abstract INTRODUCTION We examined the associations of polygenic risk score (PRS) with Alzheimer’s disease (AD) and plasma biomarkers in the Chinese population. METHODS This population-based study used baseline data from MIND-China (2018; n = 4873) and follow-up...
by Clinical Neuropsychologist | Thursday, August 22, 2024 | Dementia
Abstract INTRODUCTION Reduced brain energy metabolism, mammalian target of rapamycin (mTOR) dysregulation, and extracellular amyloid beta (Aβ) oligomer (xcAβO) buildup are some well-known Alzheimer’s disease (AD) features; how they promote neurodegeneration is...
by Clinical Neuropsychologist | Wednesday, August 21, 2024 | Dementia
Abstract INTRODUCTION CT1812 is in clinical development for the treatment of Alzheimer’s disease (AD). Cerebrospinal fluid (CSF) exploratory proteomics was employed to identify pharmacodynamic biomarkers of CT1812 in mild to moderate AD from two independent...
by Clinical Neuropsychologist | Wednesday, August 21, 2024 | Dementia
Abstract Neurogenesis persists throughout adulthood in the hippocampus and contributes to specific cognitive functions. In Alzheimer’s disease (AD), the hippocampus is affected by pathology and functional impairment early in the disease. Human AD patients have...
by Clinical Neuropsychologist | Wednesday, August 21, 2024 | Dementia
Alzheimer’s &Dementia, EarlyView. If you do not see content above, kindly GO TO SOURCE. Not all publishers encode content in a way that enables republishing at Neuro.vip. This post is Copyright: Sarah Walter, Rochelle Long, Cynthia Huling Hummel | August 21,...